Literature DB >> 6817705

Effect of allopurinol on Trypanosoma cruzi: metabolism and biological activity in intracellular and bloodstream forms.

R L Berens, J J Marr, F S Steele da Cruz, D J Nelson.   

Abstract

Allopurinol (4-hydroxypyrazolo [3,4-d]pyrimidine) is an effective agent in vitro against Trypanosoma cruzi. The important forms of this parasite, with respect to the pathogenesis of Chagas' disease in man, are the bloodstream (trypomastigote) and the intracellular forms. Experiments with radiolabeled allopurinol and analysis of the metabolic products of this compound by high-performance liquid chromatography showed that both the bloodstream and the intracellular forms of T. cruzi metabolize allopurinol in the same manner as has been shown for the epimastigotes in vitro. The metabolic pathways for pyrazolopyrimidines in the pathogenic forms were demonstrated with organisms isolated from infected animals and a tissue culture system infected with T. cruzi. Treatment of infected tissue culture with allopurinol eradicated the infection. This investigation implies that allopurinol may be useful in chemotherapy of T. cruzi infections, a supposition which has been borne out in one animal study.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817705      PMCID: PMC183810          DOI: 10.1128/AAC.22.4.657

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Isolation of blood and intracellular forms of Trypansoma cruzi from rats and other rodents and preliminary studies of their metabolism.

Authors:  W E Gutteridge; B Cover; M Gaborak
Journal:  Parasitology       Date:  1978-04       Impact factor: 3.234

2.  Antibody-induced capping of the intracellular stage of Trypanosoma cruzi.

Authors:  W Leon; F Villalta; T Queiroz; A Szarfman
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

3.  Comparative blocking actions of methylated 3-quinuclidinyl and 3-tropinyl residues in cholinergic systems.

Authors:  S L Friess; W V Hudak; R C Durant; H L Martin
Journal:  Biochem Pharmacol       Date:  1973-09-01       Impact factor: 5.858

4.  Trypanosoma cruzi: allopurinol in the treatment of mice with experimental acute Chagas disease.

Authors:  J L Avila; A Avila
Journal:  Exp Parasitol       Date:  1981-04       Impact factor: 2.011

5.  The growth of Trypanosoma cruzi in human diploid cells for the production of trypomastigotes.

Authors:  C J Sanderson; J A Thomas; C E Twomey
Journal:  Parasitology       Date:  1980-02       Impact factor: 3.234

6.  Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani.

Authors:  R L Berens; J J Marr; D J Nelson; S W LaFon
Journal:  Biochem Pharmacol       Date:  1980-09-01       Impact factor: 5.858

7.  Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation.

Authors:  D J Nelson; S W LaFon; J V Tuttle; W H Miller; R L Miller; T A Krenitsky; G B Elion; R L Berens; J J Marr
Journal:  J Biol Chem       Date:  1979-11-25       Impact factor: 5.157

8.  Antitrypanosomal effect of allopurinol: conversion in vivo to aminopyrazolopyrimidine nucleotides by Trypanosoma curzi.

Authors:  J J Marr; R L Berens; D J Nelson
Journal:  Science       Date:  1978-09-15       Impact factor: 47.728

9.  Pyrazolopyrimidine metabolism in African trypanosomes: metabolic similarities to Trypanosoma cruzi and Leishmania spp.

Authors:  R L Berens; J J Marr; R Brun
Journal:  Mol Biochem Parasitol       Date:  1980-04       Impact factor: 1.759

10.  Metabolism of pyrazolo(3,4-d)pyrimidines in Leishmania braziliensis and Leishmania donovani. Allopurinol, oxipurinol, and 4-aminopyrazolo(3,4-d)pyrimidine.

Authors:  D J Nelson; C J Bugge; G B Elion; R L Berens; J J Marr
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

View more
  14 in total

1.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

2.  Methodological advances in drug discovery for Chagas disease.

Authors:  Juan M Bustamante; Rick L Tarleton
Journal:  Expert Opin Drug Discov       Date:  2011-06       Impact factor: 6.098

3.  Pep5, a Fragment of Cyclin D2, Shows Antiparasitic Effects in Different Stages of the Trypanosoma cruzi Life Cycle and Blocks Parasite Infectivity.

Authors:  Christiane Bezerra de Araujo; Loyze Paola de Lima; Simone Guedes Calderano; Flávia Silva Damasceno; Ariel M Silber; Maria Carolina Elias
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Biological action of inosine analogs in Leishmania and Trypanosoma spp.

Authors:  J J Marr; R L Berens; N K Cohn; D J Nelson; R S Klein
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  Activity of P536, a UDP-glucose analog, against Trypanosoma cruzi.

Authors:  A Alcina; M Fresno; B Alarcón
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs.

Authors:  Noelia L Grosso; Jacqueline Bua; Alina E Perrone; Mariela N Gonzalez; Patricia L Bustos; Miriam Postan; Laura E Fichera
Journal:  Exp Parasitol       Date:  2010-05-21       Impact factor: 2.011

7.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  In vivo activity of (8-hydroxymethylen)-trieicosanyl acetate against Trypanosoma cruzi during acute phase of the infection.

Authors:  Matilde Jiménez-Coello; Karla Yolanda Acosta-Viana; Maria Salud Pérez G; Eugenia del S Guzmán-Marín
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-07-03

9.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

10.  In vitro and in vivo activities of formycin B against Trypanosoma cruzi.

Authors:  R E McCabe; J S Remington; F G Araujo
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.